Lumos Pharma (LUMO)
(Delayed Data from NSDQ)
$2.81 USD
-0.02 (-0.71%)
Updated Apr 30, 2024 03:57 PM ET
After-Market: $2.87 +0.06 (2.14%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
LUMO 2.81 -0.02(-0.71%)
Will LUMO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for LUMO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LUMO
UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
LUMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lumos Pharma (LUMO) Reports Q3 Loss, Lags Revenue Estimates
Lumos Pharma (LUMO) Reports Q2 Loss, Tops Revenue Estimates
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Top Estimates
Other News for LUMO
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
Lumos Pharma’s LUM-201 Receives ‘Buy’ Rating on Strong Market Position and Promising Trial Outcomes
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
Lumos Pharma receives notice of allowance from USPTO for LUM-201 patent
Analysts Are Bullish on Top Healthcare Stocks: Poseida Therapeutics (PSTX), Lumos Pharma (LUMO)